

## Data Sharing Statement

<b>Article Info</b>	<a href="https://dx.doi.org/10.21037/jtd-23-1029">https://dx.doi.org/10.21037/jtd-23-1029</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	Clinical data of the patients will be shared, including primary symptoms, risk factors associated with lung cancer, mutational profiles identified through next-generation sequencing, the overall survival and progression-free survival time.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	The informed consent form for the study will be shared, and other documents will be provided if needed.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years from the publication date, as the data obtained may become outdated over time.
7	To whom will you share the data?	Oncologists and pulmonologists interested in NGS in lung cancer patients within the Latin American population.
8	For what type of analysis or purpose?	To assess the primary alterations found in this population and their impact on progression-free survival and overall survival.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: consultaoncologiainer@gmail.com
10	Any other restrictions?	We will assess the potential benefits and risks for each request and then provide the data that can be shared.